Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
sal Polyps (sal Polyposis) - Overview
sal Polyps (sal Polyposis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
sal Polyps (sal Polyposis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
sal Polyps (sal Polyposis) - Companies Involved in Therapeutics Development
AptysBio Inc
ConMed Biosciences Inc
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Kyowa Kirin Co Ltd
Novartis AG
OptiNose Inc
Pfizer Inc
Suzhou Connect Biopharmaceuticals Ltd
sal Polyps (sal Polyposis) - Drug Profiles
benralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etokimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fevipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propiote - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mepolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06817024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sal Polyps (sal Polyposis) - Dormant Projects
sal Polyps (sal Polyposis) - Discontinued Products
sal Polyps (sal Polyposis) - Product Development Milestones
Featured News & Press Releases
Apr 12, 2021: Novartis receives FDA approval of Xolair (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
Dec 08, 2020: FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with sal polyps
Dec 01, 2020: Genentech announces FDA approval of Xolair (omalizumab) for adults with sal polyps
Oct 29, 2020: GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additiol eosinophil-driven diseases
Sep 10, 2020: AstraZeneca reports positive results from OSTRO trial of Fasenra
Aug 10, 2020: AptysBio reports top-line data from interim alysis of ECLIPSE phase 2 clinical trial of Etokimab in chronic rhinosinusitis with sal polyps
Aug 06, 2020: Novartis receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with sal polyps
Jul 08, 2020: Optinose announces XHANCE co-promotion agreement with Kal?o
Jun 26, 2020: Novartis receives positive CHMP opinion for new Xolair indication to treat severe chronic rhinosinusitis with sal polyps
Apr 03, 2020: Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with sal polyps
Dec 17, 2019: Optinose announces peer-reviewed publication of the fourth major XHANCE registration trial
Dec 11, 2019: FDA agrees to review Novartis’ sBLA of Xolair to treat sal polyps
Sep 12, 2019: Optinose announces $150 million debt fincing from Pharmakon
Jun 03, 2019: Xolair (Omalizumab) significantly reduced sal polyps and congestion symptoms in adults with chronic rhinosinusitis with sal polyps in two phase III studies
Feb 19, 2019: Optinose announces issuance of four additiol U.S. patents covering XHANCE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Nasal Polyps (Nasal Polyposis), 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Nasal Polyps (Nasal Polyposis), 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by AnaptysBio Inc, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by ConMed Biosciences Inc, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by GlaxoSmithKline Plc, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by Kyowa Kirin Co Ltd, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by Novartis AG, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by OptiNose Inc, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by Pfizer Inc, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2021
Nasal Polyps (Nasal Polyposis) - Dormant Projects, 2021
Nasal Polyps (Nasal Polyposis) - Discontinued Products, 2021